Patents Assigned to GlaxoSmithKline Biologicals, s.a.
-
Patent number: 11446370Abstract: A bioconjugate of an E. coli glucosylated O4 antigen polysaccharide covalently linked to a carrier protein and compositions thereof are provided. Also provided are recombinant host cells for producing the bioconjugate, and methods of producing the bioconjugate using the recombinant host cells. The recombinant host cells contain a nucleic acid encoding a glucosyl transferase capable of modifying the E. coli O4 antigen with glucose branching to produce the glucosylated O4 antigen polysaccharide. Bioconjugates of an E. coli glucosylated O4 antigen polysaccharide described herein can be used alone or in combination with one or more additional E. coli O-antigen polysaccharides to induce antibodies against an E. coli glucosylated antigen, and to vaccinate a subject against extra-intestinal pathogenic E. coli (ExPEC).Type: GrantFiled: March 18, 2020Date of Patent: September 20, 2022Assignees: Janssen Pharmaceuticals, Inc., GlaxoSmithKline Biologicals S.A.Inventors: Jeroen Geurtsen, Jan Theunis Poolman, Kellen Cristhina Fae, Pieter Jan Burghout, Eveline Marleen Weerdenburg, Patricia Ibarra Yon, Darren Robert Abbanat, Stefan Jochen Kemmler, Michael Thomas Kowarik, Manuela Mally, Veronica Gambillara Fonck, Martin Edward Braun, Maria Paula Carranza Sandmeier
-
Patent number: 11241495Abstract: The present application discloses an immunogenic composition comprising N. meningitidis capsular polysaccharides from at least one of serogroups A, C, W135 and Y conjugated to a carrier protein to produce a N. meningitidis capsular polysaccharide conjugate, wherein the average size of each N. meningitidis polysaccharide is above 50 kDa.Type: GrantFiled: November 2, 2018Date of Patent: February 8, 2022Assignee: Glaxosmithkline Biologicals S.A.Inventors: Ralph Leon Biemans, Dominique Boutriau, Carine Capiau, Philippe Denoel, Pierre Duvivier, Jan Poolman
-
Publication number: 20210277038Abstract: This invention relates inter alia to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.Type: ApplicationFiled: September 5, 2016Publication date: September 9, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Helene G. BAZIN-LEE, Jay T. EVANS, David BURKHART, Michael COCHRAN, David A. JOHNSON
-
Publication number: 20210269486Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.Type: ApplicationFiled: December 8, 2017Publication date: September 2, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Virginia AMMENDOLA, Stefaano COLLOCA, Alessandra VITELLI, Benjamin Wizel
-
Patent number: 11040095Abstract: HRV VP2 proteins useful as components of immunogenic compositions for the induction of cross-reactive cell-mediated immunity against human rhinovirus infection; nucleic acid constructs encoding such HRV VP2 proteins.Type: GrantFiled: October 5, 2017Date of Patent: June 22, 2021Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Catherine Marie Ghislaine Gerard, Sandra Giannini, Julien Thierry Massaux
-
Publication number: 20210162042Abstract: The present invention relates to compositions and methods for manufacturing an adjuvant comprising a saponin using a microfluidic device and to aspects thereof.Type: ApplicationFiled: March 23, 2018Publication date: June 3, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Pol HARVENGT, Philippe JEHOULET, Loic LE GOURRIEREC, Demostene SIFAKAKIS, Laurent STRODIOT
-
Publication number: 20210128474Abstract: Methods for manufacturing a non-viral delivery system comprising a liposome encapsulating an RNA using a microfluidic device and compositions for use therein are provided.Type: ApplicationFiled: May 30, 2018Publication date: May 6, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Laurent Bernard Jean STRODIOT, Geraldine MINET
-
Patent number: 10967057Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen. A particular embodiment is a nucleic acid-based vaccine construct encoding a polypeptide comprising a full-length Zika virus prME antigen. A particular embodiment is a self-replicating RNA molecule comprising a construct encoding a polypeptide comprising a full-length Zika virus prME antigen.Type: GrantFiled: June 1, 2017Date of Patent: April 6, 2021Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Dong Yu, Mayuri Sharma
-
Publication number: 20210085772Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.Type: ApplicationFiled: October 2, 2020Publication date: March 25, 2021Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Fabiana FERNANDEZ, Michael KOWARIK, Michael WACKER, Michael WETTER
-
Publication number: 20200323896Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.Type: ApplicationFiled: January 13, 2020Publication date: October 15, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrew GEALL, Katrin RAMSAUER, Gillis OTTEN, Christian Walter MANDL
-
Patent number: 10695424Abstract: The present invention provides compositions, methods and processes for the maturation of submicron liposome compositions comprising a lipid, a sterol, and a saponin.Type: GrantFiled: December 5, 2017Date of Patent: June 30, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Philippe Cara, Veronique Monique Roberte Henderickx, Vinciane Martha De Cupere, Carine Berthe Ghislaine De Kesel
-
Patent number: 10688168Abstract: Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition comprising an M72 related antigen and wherein a subsequent administration is delayed.Type: GrantFiled: April 2, 2015Date of Patent: June 23, 2020Assignee: GlaxoSmithKline Biologicals S.A.Inventors: William Ripley Ballou, Jr., Marie-Ange Demoitie, Marie-Noelle Renelle Donner, Nadia Ouaked, Stephane Theophile Temmerman
-
Patent number: 10669318Abstract: The present invention relates to a process for conjugation of an antigen.Type: GrantFiled: March 5, 2012Date of Patent: June 2, 2020Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Leon Biemans, Pierre Duvivier, Ollivier Francis Nicolas Gavard
-
Patent number: 10646564Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.Type: GrantFiled: February 21, 2019Date of Patent: May 12, 2020Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
-
Patent number: 10646566Abstract: The present invention relates to immunogenic compositions and methods for producing them, and in particular, immunogenic compositions comprising a protein antigen cross linked to an oxoadenine adjuvant.Type: GrantFiled: March 9, 2016Date of Patent: May 12, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: David Burkhart, Michael Cochran, Christopher W Cluff, Daniel Larocque, Helene G Bazin-Lee, Julien St Jean
-
Patent number: 10639361Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.Type: GrantFiled: June 25, 2019Date of Patent: May 5, 2020Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventor: Martine Marchand
-
Publication number: 20200123571Abstract: The present invention relates to nucleic acid constructs capable of encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, and to immunogenic compositions comprising such nucleic acid constructs and a pharmaceutically acceptable carrier. Such nucleic acid constructs and immunogenic compositions are useful in the treatment of persistent HPV infection and low-grade HPV lesions, particularly infections and lesions of human anogenital epithelial tissue, such as cervical epithelia.Type: ApplicationFiled: September 27, 2017Publication date: April 23, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Wivine BURNY, Cindy CASTADO, Sandra GIANNINI, Julien Thierry MASSAUX
-
Publication number: 20200113830Abstract: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass above 3 kDa but less than 11 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is above 3 kDa but less than 11 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen.Type: ApplicationFiled: December 16, 2019Publication date: April 16, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.Inventors: Andrew GEALL, Ayush VERMA
-
Publication number: 20200102405Abstract: A method of lipopolysaccharide (LPS) extraction from gram negative bacterial cells is provided, said method comprising a step of extracting LPS from the gram negative bacterial cell in a LPS extraction solution comprising a salt, water, an alcohol, and a further organic solvent. Compositions and uses of the extracted LPS are also provided.Type: ApplicationFiled: December 21, 2016Publication date: April 2, 2020Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.Inventors: Jeffrey A. KERN, Chad FARRENBURG
-
Patent number: 10583185Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.Type: GrantFiled: August 24, 2016Date of Patent: March 10, 2020Assignees: GlaxoSmithKline Biological S.A., Janssen Pharmaceuticals, Inc.Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally